{"id":"NCT03829319","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)","officialTitle":"A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-25","primaryCompletion":"2023-08-11","completion":"2024-08-30","firstPosted":"2019-02-04","resultsPosted":"2025-02-21","lastUpdate":"2025-09-09"},"enrollment":761,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Nonsquamous Non-small Cell Lung Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]},{"type":"DRUG","name":"Lenvatinib","otherNames":["MK-7902","E7080"]},{"type":"DRUG","name":"Placebo matching lenvatinib","otherNames":[]}],"arms":[{"label":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","type":"EXPERIMENTAL"},{"label":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer.\n\nThe primary study hypotheses state that: 1) the combination of lenvatinib + platinum doublet chemotherapy + pembrolizumab prolongs Progression-free Survival (PFS) as assessed by blinded independent central review (BICR) per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RESIST 1.1) compared to matching placebo + platinum doublet chemotherapy + pembrolizumab, and 2) the combination of lenvatinib + platinum doublet chemotherapy + pembrolizumab prolongs Overall Survival (OS) compared to matching placebo + platinum doublet chemotherapy + pembrolizumab.","primaryOutcome":{"measure":"Part 1: Number of Participants With a Dose-limiting Toxicity (DLT)","timeFrame":"Cycle 1; each cycle is 21 days (up to 21 days)","effectByArm":[{"arm":"Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":27},"locations":{"siteCount":158,"countries":["United States","Argentina","Australia","Canada","Chile","China","France","Germany","Israel","Japan","New Zealand","Poland","Russia","South Korea","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["40419140"],"seeAlso":["https://www.merckclinicaltrials.com/"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":13},"commonTop":["Anaemia","Neutrophil count decreased","Nausea","Alanine aminotransferase increased","Platelet count decreased"]}}